OPKO Health Inc. Common Stock (OPK)
Stock · NASDAQ · Health Care
$1.54as of 10/16/2026
Price chart
Active signals
OPK Signal Track Record
How signals performed across all stocks →What OPK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -0.7% | 49% | September 2, 2026 |
| Bollinger Band Breakdown | 21 | +5.5% | 62% | October 6, 2026 |
| Bollinger Band Breakout | 22 | -4.8% | 27% | September 2, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -5.2% | 46% | May 26, 2026 |
| Any 20-session window (baseline) | -1.4% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OPK
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 2,275
- Website
- www.opko.com/
Fundamentals
- 1-day range
- $1.48$1.7
- Market cap
- $985.15M
- P/E (trailing)
- —
- P/E (forward)
- -4.69
- EPS (trailing)
- $-0.10
- Dividend yield
- —
- Beta
- 1.53
- Avg. volume
- 4.05M
How OPKO Health Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
OPKO Health Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
- JANXJanux Therapeutics Inc. Common Stock$16.51▼ 4.68%Market cap $981.85MP/E —$12.12$35.34
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- OMEROmeros Corporation Common Stock$16.2▼ 13.78%Market cap $951.74MP/E 10.87$4.06$21.24
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
| JANX Janux Therapeutics Inc. Common Stock | $981.85M | — | $16.51 | ▼ 4.68% | $12.12$35.34 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| OMER Omeros Corporation Common Stock | $951.74M | 10.87 | $16.2 | ▼ 13.78% | $4.06$21.24 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4benzinga · 10/16/2026
- Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing DealYahoo · 10/9/2026
- Bruker Gains 66.3% in a Year: What's Driving the Rally?Yahoo · 10/8/2026
- 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker ResearchYahoo · 10/8/2026
- Here's Why You Should Retain WAT Stock in Your Portfolio for NowYahoo · 10/8/2026
- BDX Expands U.S. Manufacturing With $19B Healthcare InvestmentYahoo · 10/7/2026
- Reasons to Add Globus Medical Stock to Your Portfolio NowYahoo · 10/7/2026
- Cautionary Tales On Why You Should Ignore Insider BuyingSeekingAlpha · 10/7/2026
- Here's Why You Should Add Merit Medical Stock to Your Portfolio NowYahoo · 10/6/2026
Insider Activity
Insider Actions →- Logal Adam · July 24, 2026 · Tax Withholding53.3K @ $1.22
- Steven D. Rubin · July 24, 2026 · Tax Withholding53.3K @ $1.22
- Lachman Prem A · June 18, 2026 · Grant30.0K
- Yu Alice Lin-Tsing · June 18, 2026 · Grant30.0K
- UPPALURI SUBBARAO V · June 18, 2026 · Grant80.0K
- PAGANELLI JOHN A · June 18, 2026 · Grant30.0K
- Richard C. Pfenniger Jr. · June 18, 2026 · Grant60.0K
- MEDEL ROGER MD · June 18, 2026 · Grant30.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 181.30M
- Total value held
- $204.88M
- Institutional holders
- 226
- Unknown47.79M
- Unknown36.23M
- Unknown14.50M
- Unknown11.30M
- Unknown9.50M
- Unknown7.68M
- Unknown6.07M
- Unknown4.25M
- Unknown3.62M
- Unknown3.57M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
OPKO Health Shares Rise on $722M BioReference Asset Sale
OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.
OPKO Health Shares Rise on $722M BioReference Asset Sale. OPKO Health announced it sold BioReference laboratory assets to Labcorp for $722 million, a key part of Labcorp’s up to $872 million acquisition. The transaction was reflected in a sharp increase in OPKO’s stock price. The deal highlights OPKO’s focus on divesting non‑core assets. The move follows Labcorp’s broader strategy to expand its laboratory services.